Bio-Matrix Scientific Group Inc. Subsidiary Regen BioPharma Inc. Collaborates on Research Paper Analyzing the Use of Gene Sil...
June 11 2014 - 10:00AM
Marketwired
Bio-Matrix Scientific Group Inc. Subsidiary Regen BioPharma Inc.
Collaborates on Research Paper Analyzing the Use of Gene Silencing
in Heart Transplants
Data Presented in Peer Reviewed Journal Article Shows Usage of
Gene Silencing Leads to the Prolongation of Organ Transplant
Survival Without Immune Suppressants
SAN DIEGO, CA--(Marketwired - Jun 11, 2014) - Regen BioPharma
Inc. (a majority owned subsidiary of Bio-Matrix Scientific Group
Inc.) (PINKSHEETS: BMSN) announced today data demonstrating greater
than 75% survival rate in HLA mismatched hearts by combining
silencing of two genes on dendritic cells, CD40 and CD80. The
experimental animal studies demonstrated the possibility of using
gene silencing as a means of avoiding the need for lifelong immune
suppression, one of the major causes of adverse reactions
associated with heat transplantation.
The publication, which was coauthored by Regen BioPharma, with
the lead author being the company's Scientific Advisory Board
Member Dr. Wei-Ping Min, Professor at the University of Western
Ontario, Canada is freely available at:
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4040111/
"Although Regen's focus with Dr. Min is the development of
technology licensed from Benitec BioPharma to stimulate the immune
system, in the form of dCellVax, the current publication
illustrates the broad applicability of gene silencing technology,
not only for immune stimulation, but also for targeted immune
suppression," said Dr. Thomas Ichim, Chief Scientific Officer of
Regen BioPharma. "In the case of dCellVax we are blocking immune
suppressive genes to induce immune stimulation, whereas in this
case, we silenced immune stimulatory genes to block only the part
of the immune system that is responsible for rejection of heart
transplants."
Organ transplants are the only available cure for end stage
organ failure conditions such as heart, liver, and kidney
failure. Although conventional immune suppressants are
effective at blocking initial rejection of the transplanted organ,
chronic usage of immune suppressants is associated with increased
infections and incidence of cancer. This is because current
drugs to treat transplant rejection globally suppress the immune
system, making the body more susceptible to pathogens and
cancer. In contrast, the approach described in the current
publication selectively blocks the immune system from killing the
transplanted heart, while allowing other components of the immune
system to function normally.
"The current publication is an example of how work performed at
Regen in the development of dCellVax has applications outside of
its original intended field of use. Through our ongoing
collaborative efforts we plan to not only accelerate the
development of dCellVax in the area of breast cancer, but also to
advance the field of gene silencing, which may have benefits in a
wide variety of medical conditions," said David Koos, Chairman and
CEO of Regen BioPharma Inc.
Currently Regen BioPharma is progressing in its IND enabling
experiments for dCellVax, with anticipation of filing an IND in
August 2014.
About Regen BioPharma:
Regen BioPharma, Inc., a majority owned subsidiary of Bio-Matrix
Scientific Group, Inc. (PINKSHEETS: BMSN), is a biotechnology
company focused on identifying undervalued regenerative medicine
applications in the stem cell space and rapidly advancing these
technologies through pre-clinical and Phase I/ II clinical trials.
Currently the Company is focused on developing treatments for
Aplastic Anemia and a gene silencing therapy for treating cancer.
For more information refer to the company's website
http://www.regenbiopharma.com/
Disclaimer: This news release may contain forward-looking
statements. Forward-looking statements are inherently subject to
risks and uncertainties, some of which cannot be predicted or
quantified. Future events and actual results could differ
materially from those set forth in, contemplated by, or underlying
the forward-looking statements. The risks and uncertainties to
which forward looking statements are subject include, but are not
limited to, the effect of government regulation, competition and
other material risks.
Contact: Bio-Matrix Scientific Group, Inc. and Regen BioPharma
Inc. David R. Koos, PhD Chairman & Chief Executive Officer
619-702-1404 www.regenbiopharma.com